Your session is about to expire
← Back to Search
Alpha-2 Adrenergic Agonist
Clonidine for Cutaneous Nerve Itch
Phase 1
Waitlist Available
Research Sponsored by University of Minnesota
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 month
Awards & highlights
Study Summary
This trial will assess the safety and effectiveness of two drugs, clonidine and naltrexone, for treating symptoms of atopic dermatitis.
Eligible Conditions
- Cutaneous Nerve Itch
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3 month
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 month
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Reduction in Itch
Trial Design
2Treatment groups
Experimental Treatment
Group I: NaltrexoneExperimental Treatment1 Intervention
Naltrexone will be given to each subject at an oral dose of 50 mg daily. Subjects will self-administer the drug at bedtime.
Group II: ClonidineExperimental Treatment1 Intervention
Clonidine will be given orally as a starting dose of 0.1 mg daily. The drug will be administered orally by the subject at bedtime daily for four weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Clonidine
2010
Completed Phase 4
~1890
Naltrexone
2005
Completed Phase 4
~2420
Find a Location
Who is running the clinical trial?
University of MinnesotaLead Sponsor
1,380 Previous Clinical Trials
1,588,737 Total Patients Enrolled
Maria Hordinsky, MDStudy ChairUniversity of Minnesota
16 Previous Clinical Trials
450 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger